▴ Racecadotril is an oral enkephalinase inhibitor used in the treatment of acute diarrhoea. It prevents the degradation of endogenous opioids (enkephalins), thereby reducing hypersecretion of water and electrolytes into the intestinal lumen.
▴ In a randomised double-blind study in 6 adult volunteers with castor oil-induced diarrhoea, racecadotril significantly reduced stool weight and stool number in comparison with placebo. Similar results have been obtained in treating castor oil-induced diarrhoea in rats.
▴ Racecadotril was significantly more effective than placebo in randomised double-blind studies in adults or children with diarrhoea (of infectious origin or in adults with HIV infection).
▴ In well controlled trials, racecadotril had efficacy similar to that of loperamide and was generally as effective as loperamide-oxide.
▴ Racecadotril had a similar tolerability profile to placebo, and was better tolerated than loperamide, in adults and children with diarrhoea. It caused significantly less constipation after resolution of diarrhoea than loperamide.
KeywordsLoperamide Acute Diarrhoea Infectious Origin Stool Weight Racecadotril
- 10.Bioprojet Pharma. Tiorfan® acétorphan. Product monograph. Bioprojet Pharma. Paris, 1999. (Data on file)Google Scholar
- 11.Cézard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerance of acetorphan in infant acute diarrhea. A multicentric double blind study [abstract]. Gastroenterology 1996 Apr; 110(4) Suppl.: A795Google Scholar
- 13.Frexinos J, Sallenave J-R. Comparison of loperamide-oxide and acetorphan in acute diarrhoea [abstract no. 981]. Gut 1996; 39 Suppl. 3: A173Google Scholar
- 14.Roge J, Baumer P, Berard H, et al. The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand J Gastroenterol 1993 Apr; 28: 352–4Google Scholar
- 19.Ychou M, Rougier P, Douillard JY, et al. A phase II study of CPT-11 (irinotecan) in colorectal cancer (CRC) refractory to 5-FU, with preventive treatment of delayed diarrhea using acetorphan [abstract no. 454]. Ann Oncol 1996; 7 Suppl. 1: 128Google Scholar
- 20.Misset JL, Saliba F, Giachetti S, et al. Pathophysiology and therapy of irinotecan (CPT-11)-induced delayed diarrhea: a prospective assessment [abstract no. 455]. Ann Oncol 1996; 7 Suppl. 1: 128Google Scholar
- 21.Merrouche Y, Bugat R, Brunet R, et al. High dose acetorphan (HDA) versus acetorphan + loperamide (A+L) in the treatment of CPT-11 induced (DD) diarrhea: preliminary report of a randomized phase II study in patients (Pts) with advanced colorectal cancer (CRC) [abstract no. 487]. Proc Am Soc Clin Oncol 1996 Mar; 15: 211Google Scholar
- 22.Hagipantelli R, Misset JL, Saliba F, et al. Pathophysiology and therapy of CPT-11 induced diarrhea. Preliminary data of an ongoing phase I-II study [abstract no. 1425]. 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 18–22; Toronto, 239Google Scholar